This is a low-risk undertaking by VRTX/JNJ. Assuming that patient compliance is strong (as it ought to be in an open-label clinical setting where there are no superfluous placebo pills), the only underlying scientific issue is the PK profile of Telaprevir, which by now is well understood. With a typical non-inferiority margin for this kind of study, the likelihood of a non-inferiority finding is very high, IMO.
p.s. In my prior reply, I forgot to say that your post is not the quiz answer. The quiz answer has to do with the design of the phase-3b trial per se, not to some aspect of the overall Telaprevir program.
Market Data 
Markets 
AI
